MediPoint: Peripheral Vascular Stents：グローバル市場分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 17
1.2 List of Figures 25
2 Introduction 28
2.1 Catalyst 29
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Peripheral Artery Disease 30
3.1 Overview 30
3.2 Anatomy and Physiology 30
3.2.1 Peripheral Arteries of the Lower Extremity 31
3.3 Pathophysiology 33
3.4 Clinical Presentation 35
3.4.1 Symptoms of Peripheral Artery Disease 35
3.4.2 Risk Factors 36
3.4.3 Disease Classification 37
3.4.4 Diagnosis 38
3.5 Clinical Outcomes 39
3.5.1 Treatment Paradigm 39
3.5.2 Treatment Guidelines 39
3.5.3 Treatment Modalities 43
3.5.4 Endovascular Management of PAD 58
3.6 Epidemiology 64
3.6.1 Peripheral Artery Disease 64
3.7 Economic Impact 68
3.7.1 United States 68
3.7.2 EU 70
3.7.3 APAC 70
3.7.4 South America 71
3.8 Treatment Costs 71
4 Competitive Assessment 73
4.1 Overview 73
4.1.1 Peripheral Vascular Stent Market 73
4.2 Products 76
4.2.1 Bare Metal Stents 76
4.2.2 Drug-Eluting Stents 152
4.2.3 Covered Stents 158
4.2.4 Bioabsorbable Stents 169
5 Unmet Needs 172
5.1 Need for Better Clinical Outcomes in Specific Lesions 172
5.1.1 Chronic Total Occlusions 172
5.1.2 Long Lesions 172
5.1.3 Heavily-Calcified and Uncrossable Lesions 173
5.1.4 Bifurcation Lesions 173
5.2 Need to Improve Medical Therapy 173
5.3 Comparative Studies on Exercise Therapy 174
5.4 Addressing Complications of Lower-Extremity Bypass Surgery 174
5.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 175
5.6 Need for Better Revascularization of the Femoropopliteal Artery 176
5.7 Difficulty in Treating the Infrapopliteal Artery 177
5.8 Lack of Clinical Data 178
5.9 Limited Designs of Low-Profile Devices 178
5.10 Addressing Challenges of Peripheral Stenting 179
5.10.1 Risk of Post-Procedural Complications 179
5.10.2 In-Stent Restenosis 181
5.10.3 Stent Fracture 182
5.10.4 Long-Term Vessel Patency 183
5.10.5 Stent Material 184
5.10.6 Stent Deployment and Deliverability 184
5.10.7 Dual Anti-Platelet Therapy 185
5.10.8 Imaging 185
6 Pipeline Products 186
6.1 Overview 186
6.2 Pipeline by Phase of Development 187
6.3 Pipeline Product Profiles – Peripheral Artery Disease 189
6.3.1 Citation Stent 189
6.3.2 MR-Enhanced Stents 190
6.3.3 ArtiStent 191
6.3.4 Hybrid Dynamic Stent 191
6.3.5 Nipro Corporation Peripheral Stent 191
6.3.6 Yukon 191
6.3.7 iCAST 193
6.3.8 Peritoneal-Lined Stents 194
6.3.9 LifeJacket Stent Graft 195
6.3.10 Esprit BVS 195
6.3.11 Magic Explorer Stent 197
6.3.12 Stanza 198
6.3.13 3D Biotek Bioresorbable Stent 200
6.3.14 Archer Stent 201
6.3.15 ART Stent 202
6.3.16 Amaranth Bioabsorbable Scaffold 202
6.3.17 TephaFLEX Absorbable Peripheral Stent 202
6.3.18 Zorion Medical Stent 203
6.3.19 Summary 203
7 Clinical Trial Analysis 204
7.1 Overview 204
7.2 Trials to Watch 205
7.2.1 Abbott Vascular 205
7.2.2 Atrium Medical Corporation 206
7.2.3 Biotronik 207
7.2.4 480 Biomedical 207
7.2.5 Cook Medical 208
7.2.6 Covidien 209
7.2.7 Flexible Stenting Solutions 209
7.2.8 IDEV Technologies 210
7.2.9 Medtronic 211
7.2.10 Terumo Medical Corporation 213
8 Industry Overview 214
8.1 Procedure Trends 214
8.1.1 Factors Contributing to Rise of Peripheral Interventions 214
8.1.2 United States 214
8.1.3 EU 217
8.1.4 APAC 219
8.1.5 South America 221
8.2 Market Access 223
8.2.1 United States 223
8.2.2 EU 227
8.2.3 APAC 230
8.2.4 South America 235
8.3 Reimbursement Trends 237
8.3.1 United States 237
8.3.2 EU 240
8.3.3 APAC 242
8.3.4 South America 244
8.4 Regulatory Issues/Recalls 245
8.4.1 Regulatory Issues 245
8.4.2 Recalls 245
8.5 Mergers and Acquisitions 247
8.5.1 Abbott Laboratories 247
8.5.2 Atrium Medical Corporation 247
8.5.3 Boston Scientific Corporation 248
8.5.4 Cordis Corporation (Johnson & Johnson) 248
8.5.5 Covidien 248
8.5.6 CR Bard 249
8.5.7 Medtronic 249
8.5.8 Nexeon Stent 249
8.5.9 Terumo Corporation 250
9 Current and Future Players 251
9.1 Overview 251
9.2 Trends in Corporate Strategy 252
9.3 Company Profiles 255
9.3.1 Abbott Vascular 255
9.3.2 Amaranth Medical 257
9.3.3 Arterial Remodeling Technologies 258
9.3.4 Atrium Medical Corporation 260
9.3.5 Bard Peripheral Vascular (C.R. Bard) 262
9.3.6 Biotronik 264
9.3.7 Boston Scientific Corporation 266
9.3.8 3D Biotek 268
9.3.9 480 Biomedical 269
9.3.10 Cook Medical 271
9.3.11 Cordis Corporation (Johnson & Johnson) 273
9.3.12 CorInnova 275
9.3.13 Covidien 277
9.3.14 Cytograft Tissue Engineering 279
9.3.15 Flexible Stenting Solutions 281
9.3.16 IDEV Technologies 283
9.3.17 Kyoto Medical Planning 284
9.3.18 Medtronic 287
9.3.19 Nexeon Stent 289
9.3.20 Nipro Corporation 291
9.3.21 NovoStent Corporation 292
9.3.22 OptiMed 294
9.3.23 PeriTec Biosciences 295
9.3.24 Synergy Flow 297
9.3.25 Tepha 298
9.3.26 Terumo Corporation 300
9.3.27 TissueGen 302
9.3.28 Translumina 304
9.3.29 Vascular Concepts 306
9.3.30 Veryan Medical 307
9.3.31 VueKlar Cardiovascular 309
9.3.32 W.L. Gore & Associates 310
9.3.33 Zorion Medical 312
10 Market Drivers, Opportunities and Barriers 314
10.1 Market Drivers 314
10.1.1 Rising Prevalence of Disease 315
10.1.2 Long-Term Vessel Patency 316
10.1.3 Reducing the Risk of Restenosis 317
10.1.4 Low-Profile Stent System 317
10.1.5 Self-Expanding Nitinol Stents 319
10.1.6 Limb Amputation 319
10.1.7 Cost Considerations 320
10.1.8 Availability of Long-Term Data 320
10.1.9 Avoiding Stent-in-Stent Procedures 321
10.1.10 Reducing the Need for Dual Anti-Platelet Therapy 321
10.1.11 Accurate Stent Placement 322
10.1.12 Expected Launch of Vascular Stent Products in the US 322
10.2 Opportunities 323
10.2.1 Peripheral Stent Market 323
10.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 325
10.2.3 Biodegradable and Bioabsorbable Stents 326
10.2.4 Target High-Risk Patients 327
10.2.5 Launch Vascular Stents in the Japanese Market 327
10.2.6 Emerging Markets 328
10.3 Market Barriers 328
10.3.1 Slow Adoption 328
10.3.2 High Selling Prices 332
10.3.3 Lack of Reimbursement 332
10.3.4 Substitutes 333
11 Market Analysis by Segment 334
11.1 Global Market Overview 334
11.2 Type of Peripheral Artery in the Lower Extremity 336
11.2.1 Iliac Artery Revascularization 336
11.2.2 Femoropopliteal Artery Revascularization 338
11.2.3 Infrapopliteal Artery Revascularization 339
12 Country Outlooks and Forecasts 341
12.1 Overview 341
12.2 United States 343
12.2.1 Overview 343
12.2.2 Market Analysis 343
12.3 France 346
12.3.1 Overview 346
12.3.2 Market Analysis 346
12.4 Germany 348
12.4.1 Overview 348
12.4.2 Market Analysis 348
12.5 Italy 351
12.5.1 Overview 351
12.5.2 Market Analysis 351
12.6 Spain 353
12.6.1 Overview 353
12.6.2 Market Analysis 353
12.7 United Kingdom 356
12.7.1 Overview 356
12.7.2 Market Analysis 356
12.8 Japan 359
12.8.1 Overview 359
12.8.2 Market Analysis 359
12.9 Brazil 361
12.9.1 Overview 361
12.9.2 Market Analysis 361
12.10 China 364
12.10.1 Overview 364
12.10.2 Market Analysis 364
12.11 India 366
12.11.1 Overview 366
12.11.2 Market Analysis 366
13 Appendix 369
13.1 Bibliography 369
13.2 Abbreviations 392
13.3 Report Methodology 395
13.3.1 Overview 395
13.3.2 Coverage 395
13.3.3 Secondary Research 395
13.3.4 Forecasting Methodology 396
13.4 Physicians and Specialists Included in this Study 397
13.5 Physician Survey 399
13.6 About the Authors 400
13.6.1 Analysts 400
13.6.2 Global Head of Healthcare 401
13.7 About MediPoint 401
13.8 About GlobalData 401
13.9 Contact Us 402
13.10 Disclaimer 402